Healthcare >> CEO Interviews >> April 1, 2003
JOHN R. PLACHETKA is President, Chief Executive Officer and
Chairman of the Board of Directors of POZEN, Inc. Prior to
founding POZEN in 1996, Dr. Plachetka was Vice President of
Development at Texas Biotechnology Corporation for two years,
where he led the development of argatroban, a novel thrombin
blocker. Previously, he served for two years as President and
Chief Executive Officer of Clinical Research Foundation-America,
a top-10 contract clinical research company in the U.S. This was
preceded by a nine-year career at Glaxo Inc. where Dr. Plachetka
held various executive positions including director of
cardiovascular clinical research and led the US development
program for Imitrex', Trandate', and a thromboxane antagonist. He
also participated in the development program for Zantac' tablets
and injection. Dr. Plachetka was formerly Assistant Professor of
Pharmacy Practice and Cardiovascular and Thoracic Surgery at the
University of Arizona. He earned his Bachelor's degree in
Pharmacy from the University of Illinois College of Pharmacy and
holds a Doctor of Pharmacy degree from the University of
Missouri-Kansas City. Profile
and what you see as the business opportunity today?
Dr. Plachetka: POZEN is a pharmaceutical development company
committed to
